Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): Comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up

BMC Ophthalmology

Volumn 13, Issue 1, 2013, Pages

  Matsumiya, Wataru ^a   Honda, Shigeru ^a   Kusuhara, Sentaro ^a   Tsukahara, Yasutomo ^a   Negi, Akira ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Intravitreal ranibizumab; One year outcome; Polypoidal choroidal vasculopathy; Typical neovascular age related macular degeneration

Indexed keywords

ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; RANIBIZUMAB;

AGED; ARTICLE; CHOROID DISEASE; FEMALE; FOLLOW UP; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; POLYP; RETINA MACULA DEGENERATION; RETROSPECTIVE STUDY; STATISTICAL MODEL; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; LOGISTIC MODELS; MACULAR DEGENERATION; MALE; MIDDLE AGED; POLYPS; RETROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 84875688194     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-13-10     Document Type: Article

References (40)

1. Age-related macular degeneration and recent developments: new hope for old eyes? Morris B, Imrie F, Armbrecht AM, Dhillon B, Postgrad Med J 2007 83 301 307 10.1136/pgmj.2006.052944 17488857
2. Ranibizumab for neovascular age-related macular degeneration. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J, Am J Health Syst Pharm 2008 65 1805 1814 10.2146/ajhp070342 18796421
3. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group, N Engl J Med 2006 355 1432 1444 10.1056/NEJMoa062655 17021319
4. Ranibizumab for neovascular age-related macular degeneration. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group, N Engl J Med 2006 355 1419 1431 10.1056/NEJMoa054481 17021318
5. EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Tano Y, Ohji M, EXTEND-I Study Group, Acta Ophthalmol 2010 88 309 316 10.1111/j.1755-3768.2009.01843.x 20163368
6. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular Age-related macular degeneration. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M, Am J Ophthalmol 2007 143 566 583 10.1016/j.ajo.2007.01.028 17386270
7. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prünte C, Schmidt-Erfurth U, Tano Y, Wolf S, Br J Ophthalmol 2010 94 2 13 10.1136/bjo.2009.159160 19443462
8. Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patients. Suzuki M, Gomi F, Sawa M, Tsujikawa M, Sakaguchi H, Jpn J Ophthalmol 2010 54 124 128 10.1007/s10384-009-0775-3 20401560
9. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Maruko I, Iida T, Saito M, Nagayama D, Saito K, Am J Ophthalmol 2007 144 15 22 10.1016/j.ajo.2007.03.047 17509509
10. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, Tano Y, Br J Ophthalmol 2008 92 70 73 10.1136/bjo.2007.122283 17567661
11. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ, Harding SP, Am J Ophthalmol 2010 150 666 673 10.1016/j.ajo.2010.05.035 20719300
12. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Yamashiro K, Tomita K, Tsujikawa A, Nakata I, Akagi-Kurashige Y, Miyake M, Ooto S, Tamura H, Yoshimura N, Am J Ophthalmol 2012 154 125 136 10.1016/j.ajo.2012.01.010 22465368
13. Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Matsumiya W, Honda S, Bessho H, Kusuhara S, Tsukahara Y, Negi A, J Ophthalmol 2011 2011 742020 21772985
14. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ, CATT Research Group, N Engl J Med 2011 364 1897 1908 21526923
15. Idiopathic polypoidal choroidal vasculopathy (IPCV). Yannuzzi LA, Sorenson J, Spaide RF, Lipson B, Retina 1990 10 1 8 1693009
16. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA, Arch Ophthalmol 1997 115 478 485 10.1001/archopht.1997.01100150480005 9109756
17. Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Uyama M, Matsubara T, Fukushima I, Matsunaga H, Iwashita K, Nagai Y, Takahashi K, Arch Ophthalmol 1999 117 1035 1042 10.1001/archopht.117.8.1035 10448746
18. Indocyanine green videoangiography of idiopathic polypoidal horoidal vasculopathy. Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA, Retina 1995 15 100 110 10.1097/00006982-199515020-00003 7542796
19. Polypoidal choroidal vasculopathy. Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA, Surv Ophthalmol 2004 49 25 37 10.1016/j.survophthal.2003. 10.007 14711438
20. Guidance for the treatment of neovascular age-related macular degeneration. Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcòstegui B, Cunha-Vaz J, Gaudric A, Leys A, Schlingemann RO, European Society for Retina Specialists' Guidelines Committee (EURETINA), Acta Ophthalmol Scand 2007 85 486 494 10.1111/j.1755-3768.2007.00979.x 17655610
21. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American academy of ophthalmology. Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, Recchia FM, American Academy of Ophthalmology, Ophthalmology 2008 115 1837 1846 10.1016/j.ophtha.2008.08.012 18929163
22. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. Mekjavic PJ, Kraut A, Urbancic M, Lenassi E, Hawlina M, Acta Ophthalmol 2011 89 647 653 v 10.1111/j.1755-3768.2009.01740.x 19860774
23. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G, SUSTAIN Study Group, Ophthalmology 2011 118 663 671 10.1016/j.ophtha.2010.12.019 21459217
24. One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups. Kang S, Roh YJ, Jpn J Ophthalmol 2009 53 389 395 10.1007/s10384-009-0670-y 19763757
25. One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy. Song MH, Ryu HW, Roh YJ, Ophthalmologica 2011 226 119 126 10.1159/000329466 21757883
26. Clinicopathologic findings in polypoidal choroidal vasculopathy. Nakashizuka H, Mitsumata M, Okisaka S, Shimada H, Kawamura A, Mori R, Yuzawa M, Invest Ophthalmol Vis Sci 2008 49 4729 4737 10.1167/iovs.08-2134 18586873
27. Polypoidal choroidal vasculopathy in elderly Chinese patients. Wen F, Chen C, Wu D, Li H, Graefes Arch Clin Exp Ophthalmol 2004 242 625 629 10.1007/s00417-003-0667-z 15257461
28. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Lai TY, Chan WM, Liu DT, Luk FO, Lam DS, Br J Ophthalmol 2008 92 661 666 10.1136/bjo.2007.135103 18356265
29. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Kokame GT, Yeung L, Lai JC, Br J Ophthalmol 2010 94 297 301 10.1136/bjo.2008.150029 19726427
30. Distinct characteristics of circulating vascular endothelial growth factor-a and C levels in human subjects. Wada H, Ura S, Kitaoka S, Satoh-Asahara N, Horie T, Ono K, Takaya T, Takanabe-Mori R, Akao M, Abe M, Morimoto T, Murayama T, Yokode M, Fujita M, Shimatsu A, Hasegawa K, PLoS One 2011 6 29351 10.1371/journal.pone.0029351 22206010
31. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, Guiberteau B, Quentel G, Am J Ophthalmol 2009 148 409 413 10.1016/j.ajo.2009.04.001 19477713
32. Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S, Graefes Arch Clin Exp Ophthalmol 2013 251 453 458 10.1007/s00417-012-2038-0 22573410
33. Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy. Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia-Feijoo J, Leila M, Garcia-Sanchez J, Eur J Ophthalmol 2008 18 645 648 18609492
34. Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months. Hikichi T, Ohtsuka H, Higuchi M, Matsushita T, Ariga H, Kosaka S, Matsushita R, Takami K, Am J Ophthalmol 2010 150 674 682 10.1016/j.ajo.2010.05.026 20691424
35. Natural course and funduscopic findings of polypoidal choroidal vasculopathy in a Japanese population over 1 year of follow-up. Bessho H, Honda S, Imai H, Negi A, Retina 2011 31 1598 1602 10.1097/IAE.0b013e31820d3f28 21478804
36. Predictive factors of resolved retinal fluid after intravitreal ranibizumab for polypoidal choroidal vasculopathy. Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S, Br J Ophthalmol 2011 95 1555 1559 10.1136/bjophthalmol- 2011-300285 21890787
37. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, MARINA Study Group, Ophthalmology 2007 114 246 252 10.1016/j.ophtha.2006.10.045 17270674
38. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, Ikuno Y, Tano Y, Ophthalmology 2008 115 141 146 10.1016/j.ophtha.2007.02.031 17582498
39. Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan. Honda S, Kurimoto Y, Kagotani Y, Yamamoto H, Takagi H, Uenishi M, Jpn J Ophthalmol 2009 53 593 597 10.1007/s10384-009-0741-0 20020237
40. EVEREST STUDY: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH, Retina 2012 32 1453 1464 10.1097/IAE.0b013e31824f91e8 22426346